WNY1613
WNY1613 is a potent and selective PI3Kδ inhibitor with piperazinone-containing purine scaffold. WNY1613 induces cancer cell apoptosis and inhibits the phosphorylation of PI3K downstream components in NHL cell lines. WNY1613 exhibits anti-NHL activity in vitro and in vivo.
For research use only. We do not sell to patients.
- CAS No.: 2650546-39-5
- Formula: C29H35N9O3
- Molecular Weight:557.65
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| Granta-519 | IC50 |
0.038 μM
Compound: 30; WNY1613
|
Antiproliferative activity against human Granta-519 cells assessed as cell viability by non-radioactive cell proliferation MTT assay
Antiproliferative activity against human Granta-519 cells assessed as cell viability by non-radioactive cell proliferation MTT assay
|
[PMID: 36503229] |
| JeKo-1 | IC50 |
0.038 μM
Compound: 30; WNY1613
|
Antiproliferative activity against human JeKo-1 cells assessed as cell viability by non-radioactive cell proliferation MTT assay
Antiproliferative activity against human JeKo-1 cells assessed as cell viability by non-radioactive cell proliferation MTT assay
|
[PMID: 36503229] |
| NAMALVA | IC50 |
0.038 μM
Compound: 30; WNY1613
|
Antiproliferative activity against human NAMALVA cells assessed as cell viability by non-radioactive cell proliferation MTT assay
Antiproliferative activity against human NAMALVA cells assessed as cell viability by non-radioactive cell proliferation MTT assay
|
[PMID: 36503229] |
| OCI-Ly3 | IC50 |
0.038 μM
Compound: 30; WNY1613
|
Antiproliferative activity against human OCILY3 cells assessed as cell viability by non-radioactive cell proliferation MTT assay
Antiproliferative activity against human OCILY3 cells assessed as cell viability by non-radioactive cell proliferation MTT assay
|
[PMID: 36503229] |
| SUD4 | IC50 |
0.038 μM
Compound: 30; WNY1613
|
Antiproliferative activity against human SU-DHL-4 cells assessed as cell viability by non-radioactive cell proliferation MTT assay
Antiproliferative activity against human SU-DHL-4 cells assessed as cell viability by non-radioactive cell proliferation MTT assay
|
[PMID: 36503229] |
| SU-DHL-6 | IC50 |
0.038 μM
Compound: 30; WNY1613
|
Antiproliferative activity against human SU-DHL-6 cells assessed as cell viability by non-radioactive cell proliferation MTT assay
Antiproliferative activity against human SU-DHL-6 cells assessed as cell viability by non-radioactive cell proliferation MTT assay
|
[PMID: 36503229] |
| WSUDLCL2 | IC50 |
0.038 μM
Compound: 30; WNY1613
|
Antiproliferative activity against human WSUDLCL2 cells assessed as cell viability by non-radioactive cell proliferation MTT assay
Antiproliferative activity against human WSUDLCL2 cells assessed as cell viability by non-radioactive cell proliferation MTT assay
|
[PMID: 36503229] |
Chemical Information
-
CAS No. 2650546-39-5
-
Molecular Weight 557.65
-
Formula C29H35N9O3
-
SMILES
O=C1N(CC2=NC3=C(N4CCOCC4)N=C(N5C6=CC=CC=C6N=C5CC)N=C3N2C)CCN(C(C7CCC7)=O)C1
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)